Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

NCT03591874 is registered in ClinicalTrials.gov with Ocugen as lead sponsor.

NCT NCT03591874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03591874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
Lead sponsor
Ocugen
Phase
Phase 3
Overall status
Terminated
Start date
December 23, 2018
Completion date
April 30, 2020
Enrollment
59 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

brimonidine tartrate, graft versus host disease, graft vs host disease, lubricant eye drops, ocular graft vs host disease, ocular surface disease, ogvhd, ophthalmic solutions